梯瓦制药Teva Pharmaceutical Industries（TEVA）2025年第四季度及全年业绩投资人演示文稿「NYSE」（英文版）（71页）.pdf

1、Teva Pharmaceutical Industries Ltd.January 28,20262|This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995,which are based on managements current beliefs and expectations and are subject to substantial risks and uncertainties,

2、both known and unknown,that could cause our future results,performance or achievements to differ significantly from that expressed or implied by such forward-looking statements.Important factors that could cause or contribute to such differences include risks relating to:our ability to successfully

3、compete in the marketplace,including:that we are substantially dependent on our generic products;concentration of our customer base and commercial alliances among our customers;competition faced by our generic medicines from other pharmaceutical companies and changes in regulatory policy that may re

4、sult in costs and delays;delays in launches of new generic products;our ability to develop and commercialize additional pharmaceutical products in a timely manner;intense competition for our innovative medicines;our ability to achieve expected results from investments in our product pipeline;our abi

5、lity to successfully execute our Pivot to Growth strategy,including to expand our innovative and biosimilar medicines pipeline and profitably commercialize our innovative medicines and biosimilar portfolio,whether organically or through business development,to sustain and focus our portfolio of gene

6、ric medicines,and to execute on our organizational transformation and to achieve expected cost savings;and the effectiveness of our patents and other measures to protect our intellectual property rights;our significant indebtedness,which may limit our ability to incur additional indebtedness,engage